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Background: Long term oxygen therapy (LTOT) has a strong evidence base in COPD patients with respiratory
failure, but prescribing practices are recognized to need reform to ensure appropriate use and minimize costs. In
the UK, since February 2006, all Home Oxygen prescription is issued by hospitals, making respiratory specialists
totally in charge of home oxygen prescription. It has been widely noted that inappropriate home oxygen, often for
intermittent use (“short burst”), is frequently prescribed in patients with COPD and related conditions with the
intention to prevent hospital admissions outside of evidence based LTOT guidelines. We participated in a national
Lung Improvement Project aimed at making LTOT use more evidence based. We utilised this unique opportunity of
studying the effect of removal of oxygen from COPD patients (who did not meet LTOT criteria) on hospital
admission rates.
Methods: Primary and secondary care data sources were used to identify patients with COPD in a single primary
care trust who were admitted to hospital at least once due to COPD between April 2007 and November 2010.
Admission rates were compared between LTOT users and non-users, adjusted for age and COPD severity. LTOT
users were further studied for predictors of admission in those appropriately or inappropriately given oxygen
according to NICE guidance, and for admissions before and after oxygen receipt, adjusting further for co-morbidity.
Mortality and economic analyses were also conducted.
Results: Readmission was more likely in LTOT users (3.18 v 1.67 per patient, p < 0.001) after adjustment for FEV1
and age by multiple regression. When stratifying by appropriateness of LTOT prescription, adjusting also for
Charlson index and other covariates, FEV1 predicted admission in appropriate users but there were no predictors in
inappropriate users. In longitudinal analyses admission rates did not differ either side of oxygen prescription in
appropriate or inappropriate LTOT users. Specialist assessment resulted in cost savings due to reduced use of
oxygen.
Conclusions: Admission to hospital is more likely in LTOT users, independent of COPD severity. Oxygen use outside
NICE guidance does not appear to prevent admissions.* Correspondence: rmukherjee@doctors.net.uk
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Oxygen has a strong evidence base for use in respiratory
failure in chronic obstructive pulmonary disease (COPD),
following the landmark long term oxygen therapy (LTOT)
studies in the 1980s [1-3]. These studies underpin the rec-
ommendation [4] that oxygen should be used for at least
15 hours per day in patients with COPD who have a pO2
when well < = 7.3 kPa, or <8.0 kPa if polycythaemia, pul-
monary hypertension or cor pulmonale are present. In pa-
tients with less severe hypoxaemia trials are ongoing to
establish whether oxygen supplementation has a role [5].
The Royal College of Physicians [6] and the Department
of Health [7] have extensively reviewed the way in which
services are provided for oxygen use in COPD, as it became
apparent that 85000 patients in the UK receive oxygen (at
a cost to the NHS of over £110 m), yet in up to 43% of
them it is either unused or unlikely to give clinical benefit
[7]. A few cost-effectiveness studies have been conducted
in the UK, based on which a number of improvement pro-
jects for home oxygen assessment and review (HOS-AR)
services have been, and are being, conducted to determine
the best methods of reform/rationalisation [8-11].
More recently a review in the USA concluded that
LTOT was cost-effective based on quality adjusted life
years gained (QALYs) if used according to current evi-
dence [12]. Indeed most of the savings likely to result
from new HOS-AR systems are from removal of oxygen
which is not clinically indicated; this has been proven in
several studies [13,14]. Whilst LTOT prescription should
be based on blood gas results, and aims to improve sur-
vival [1-3], previous estimates of the economic value of
oxygen service reform have not taken effect on admis-
sions into account. COPD admissions are recognized as
a large burden to the UK health economy; hence we felt
that a detailed consideration of the effect of rationalizing
oxygen use on this was warranted.
The primary purpose of this audit/study was to explore
the belief relating to emergency hospital admission pre-
vention by inappropriate home oxygen prescription, which
motivates some healthcare providers to do so and con-
tinue to practise, although little robust data on this is
available. This audit/study was possible due to our hospi-
tal’s participation in a national Lung Improvement Project,
aimed at making LTOT use more evidence based.
In this study we also aimed to assess the scale of the
problem of inappropriate LTOT prescription in COPD,
the relationship of LTOT prescription to admissions,
and to model the health economics of oxygen savings
when taking admissions into account.
Methods
Patient and admission data
Data from the Secondary Uses Service (SUS) for hospital
spells involving patients from the Birmingham East andNorth (BEN) PCT admitted as an emergency and classi-
fied with a Healthcare Resource Group (HRG) code relat-
ing to COPD was identified by an information manager
within the PCT for the period 1st April 2007 to 30th No-
vember 2010. Concurrent data from Air Products, the
provider of home oxygen supplies to BEN patients, was
used to identify oxygen users; charging data enabled iden-
tification of those in receipt of LTOT. Relevant emergency
spells from the SUS dataset including length of stay (LOS)
for each spell were recorded for patients and classified ac-
cording to receipt of LTOT status (ever v never) along
with the start date of the service and, if relevant, the date
at which LTOT was withdrawn. A tag identified whether
each spell was before, during or after the provision of
LTOT. Both the SUS and Air Products database use NHS
number to identify patients, enabling date of birth and
FEV1 measurements to be gathered from primary and
secondary care records.
For LTOT users secondary care records from the oxy-
gen assessing service provider (Heart of England Founda-
tion NHS Trust; HEFT) were reviewed to determine if the
patient had ever seen a respiratory specialist and under-
gone oxygen needs assessment. Sufficient data to deter-
mine oxygen needs was defined as a definite diagnosis of
COPD (post bronchodilator FEV1/FVC <0.7), with oxygen
saturations, and ABG if saturations were < =92% when
stable. Appropriate oxygen prescription was defined as
that listed in NICE guidance [4]. Co-morbidity was re-
corded and classified using the Charlson index, chosen as
a valid method to quantify co-morbid disease [15] and
good predictor of admission [16]. Mortality and cause of
death were taken from hospital bereavement records, with
cross checking against PCT records. Patients were ex-
cluded from further analysis if the data suggested they did
not have COPD, or there were inconsistencies bringing
data quality into question.
The study was approved by the local Lung Improvement
Project Board as a retrospective audit registered with the
NHS. As it was a service evaluation by members of the
clinical team, it did not require ethics approval as autho-
rized by the Lung Improvement Programme Board consti-
tuted by National Health Service (NHS) Trusts and
conducted by its employees. No identifiable data was
viewed by anyone outside the oxygen prescribing team
who clinically managed the patients, in keeping with the
principles of the Data Protection Act 1998.
Statistical analysis
All analyses were carried out in SPSS (version 16.0). Mean
number of admissions was compared between LTOT
users and non-users with COPD using the t-test, and then
after regression, adjusting for age and FEV1 (% predicted),
used as continuous variables. In the HEFT dataset all uni-
variate comparisons of appropriate v inappropriate oxygen
Table 2 Characteristics of subset of patients with COPD






Number of admissions 1 (1–2) 2 (1–4) <0.0001
Total length of stay (days) 5 (2–12) 17 (7–34) <0.0001
FEV1 (litres) 1.14 (0.78-1.58) 0.73 (0.56-1.04) <0.0001
FEV1 (% predicted) 51 (37–70) 35 (27–50) <0.0001
Age (years) 73.95 (65.47-81.00) 72.82 (0.72) 0.759
Data is shown as median (IQR) as all were non-normally distributed. Age was
normally distributed in the LTOT group and is therefore shown as mean (SE).
This was also the only feature that did not differ between LTOT and
non-LTOT groups.
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Whitney, for parametric and non-parametric data respect-
ively, or the Chi square test for frequency variables. Multi-
variate analysis assessing associations of admission rate
examined age, FEV1, gender and Charlson index as pre-
dictors, and was carried out separately for appropriate and
inappropriate LTOT users. Missing data was dealt with on
a case basis, seeking it from additional data sources if pos-
sible. Finally paired tests were used to compare admission
rate/year either side of oxygen receipt for patients in whom
this data was available.
Economic modeling
Cost/day of LTOT was taken from typical charging data,




There were 1942 patients identified with COPD, of
whom 295 had received oxygen during the study period
(Table 1). The raw data suggested that oxygen prescrip-
tion as LTOT on discharge from hospital strongly pre-
dicted subsequent admission (3.18 v 1.67 readmissions/
patient, p = 1.8 × 10−12). Post bronchodilator spirometry
was available on 1047 (54%) of patients; a further 22%
had their COPD diagnosed by a respiratory consultant,
but raw spirometry data was not available. Characteris-
tics of the cohort with spirometry available, such that we
are confident of the diagnosis of COPD, are shown in
Table 2. Multiple regression analysis in this subgroup
seeking predictors of number of admissions showed that
neither age (p = 0.34), nor FEV1 (% predicted) were sig-
nificantly associated (p = 0.11). However LTOT remained
significantly associated, with an odds ratio of admission
of 1.53 (95% CI 1.09-1.97, p < 1.0 × 10−6) in LTOT pa-
tients. A similar relationship was seen to total length of
stay, with LTOT patients being much more likely to
have an LOS more than 6 days (OR 4.5; 95% CI 3.1-6.7,
p < 1.0 × 10−6). This emphasizes the importance of
assessing for LTOT during stability and not using it for
the sake of pure “admission avoidance” outside of the
guidelines.Table 1 Hospital spells for COPD patients stratified by
LTOT status (includes all patients classed as COPD in
hospital episode statistics/SUS Data)





21+ 2 2COPD patients given oxygen
There were 295 patients in this group, 20 were excluded
from further analysis because records showed oxygen
was removed before it was commenced, or that the pa-
tient had died before commencement, thus invalidating
their record. 263 of the patients prescribed oxygen had
seen a respiratory physician and spirometry was carried
out in 201 patients within a year of oxygen prescription.
124 had a detailed oxygen assessment including arterial
blood gas (ABG) sampling. In 38 cases oxygen could be
stopped after this assessment; a further 20 had oxygen
stopped on the basis of saturations and clinical review
alone, such that ABG was not required. This equates to
a cessation rate of 40.3% on specialist review. An add-
itional 16 patients had a palliative oxygen prescription
(died within a month of commencement, with docu-
mented terminal disease, either end stage COPD or co-
existent malignancy). In all 12 patients who had not seen
a respiratory physician there was insufficient information
to determine if oxygen was required, suggesting a strong
trend to more robust, evidence-based prescription if
seen by a specialist (p = 0.066). In patients where there
was sufficient data to assess oxygen needs, and it was
not given for palliation purposes there were no differences
in age, gender, lung function or co-morbidity (Charlson
index) between appropriate and inappropriate prescrip-
tions (all p > 0.15). Patient characteristics are shown in
Table 3.Mortality
64% (n = 176) of patients who received oxygen died during
the follow up period; of these 47% (n = 84) had a purely
respiratory cause of death and 9.1% (n = 16) a non-
respiratory cause, with the remainder having respiratory
disease listed as a contributory factor. Purely respiratory
deaths were more likely in those appropriately given oxy-
gen (p = 0.044). On the whole oxygen prescription ceased
swiftly after patients died (Table 3), although in one case it
continued for 767 days after death.
Table 3 Characteristics of patients prescribed oxygen
Age (years) 73.03 (3.13)
Male gender 119 (43.30)
FEV1 (litres) 0.85 (0.56-1.00)
FEV1 (% predicted) 47.18 (8.08)
FEV1/FVC 0.49 (0.05)
Charlson index 3.00 (0.58)
pO2 (kPa) on air 6.60 (6.20-6.73)
pCO2 (kPa) on air 5.89 (0.48)
Days received oxygen 190 (40–1289)
Time to death from oxygen being
started (days)
827.63 (165.26)
Time between death and oxygen
cessation (days)
Oxygen stopped before death 324.50 (161.00-603.75)
Oxygen stopped after death 8.50 (5.00-17.00)
The table shows the characteristics of those patients that received oxygen.
Normally distributed data is shown as mean (SEM) and non-normally distributed
data as median (IQR), whilst the single frequency variable is highlighted in bold
type and is shown as n (%).
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Regression analysis assessing predictors of admission in
those appropriately given oxygen showed that FEV1 was
the only significant predictor of readmission (p = 0.045),
whilst no predictors were found in those inappropriately
prescribed it. There were no differences in admission
frequency or length of hospital stay either before, during
or after oxygen prescription, adjusted for the time of each
period per patient (all p > 0.54) when comparing those ap-
propriately and inappropriately prescribed oxygen.
There were 48 patients in whom oxygen was started
during the study period and data available both before
and during oxygen prescription. In these patients ad-
mission rate did not differ after being given oxygen
(2.90 (3.26) v 2.17 (1.53); p = 0.15), nor did length of
stay (p = 0.94). When this group was sub-stratified by
whether oxygen prescription was appropriate or not
the significance of these figures did not change; in the
group given oxygen appropriately mean admission fre-
quency fell by 0.4/year (p = 0.31) and in those given it
inappropriately by 2/year (p = 0.29). The rate of admis-
sion in the inappropriate oxygen prescription group
was very variable, ranging from a gain of 2 to a reduc-
tion of 6 admissions. In 17 patients where oxygen had
been prescribed inappropriately rates and lengths of
stay did not differ after it was removed (both p >0.56).
In those patients inappropriately prescribed oxygen no
admissions related to harm from oxygen were identified.
Economic impact of oxygen service
No adverse impact of removal of oxygen from patients
given it outside current guidance was found on hospitaladmissions nor were there any significant benefits on hos-
pital admission rates from prescribing oxygen, regardless
of need. Consequently we anticipate no hidden economic
impact of reform of oxygen services on secondary care
usage by COPD patients in the UK. Cessation in the
40.3% of LTOT patients where prescription was inappro-
priate would save £71000 in a population of 300000
(equivalent to this PCT), and £30 million in the UK each
year, allowing for the slight increase in ambulatory oxygen
use. Oxygen cessation on registration of death could save
up to a further 10% per annum in unreformed services,
based on the average days given after death.
Discussion
Our data suggests that home oxygen prescription outside
of evidence based guidelines does not reduce admission
rates and confirms that robust oxygen assessment systems
can benefit the local health economy. This analysis holds
true in a large group with limited phenotypic data, and in
a highly characterized dataset, and even in individual pa-
tients assessed longitudinally either side of oxygen pre-
scription. This 3 level analysis is a significant strength of
our study. Many studies have attempted to define predic-
tors of exacerbations, and hospitalizations in COPD. The
ECLIPSE study identified severity of COPD, presence of
gastro-oesophageal reflux disease, poor quality of life score
and white cell count to independently predict exacerba-
tion rate, but did not report any effect of oxygen use [17].
Admission for exacerbation is more common in severe
COPD [17] and in oxygen users [18], whilst readmission
relates to BODE index [19] and psychosocial factors [20].
Since arterial oxygen levels are predicted by lung function
[21], and the BODE index has FEV1 as one of its major
components [22] taken together this data suggests that we
should expect readmission to hospital more frequently in
LTOT users due to their more severe lung disease. Our
initial analysis appeared to confirm this, in that oxygen
users throughout the PCT catchment area came into hos-
pital more often, and their lung function was worse
(Table 2). However if disease severity were the main pre-
dictor of both respiratory failure and readmission we
would have expected this difference to reduce more mark-
edly when adjusted for FEV1. Since this was not the case,
the data suggested that receipt of oxygen was adversely
impacting admissions independent of COPD severity. This
is in direct contrast to the perception amongst healthcare
providers that it may reduce admissions, and therefore
warranted further exploration. The PCT level data did not
allow us to assess appropriateness of oxygen prescription
or co-morbidity in relation to admissions, such that a
more detailed consideration of secondary care records
for those patients who had received oxygen was carried out.
The secondary care data allowed us to categorise pa-
tients according to their oxygen needs, as defined by
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morbidity by use of the Charlson index. We were also able
to look at admission rates longitudinally, according to oxy-
gen receipt status in those patients where oxygen was
commenced or removed during the data collection period.
This makes the analysis much more robust than the PCT
level results. The data showed that admissions were no
more common in patients appropriately given oxygen,
compared to those where it was given inappropriately.
Whilst COPD severity (FEV1) was a good predictor of ad-
mission in patients where LTOT was indicated, neither
this, age or co-morbidity associated with admission in
those inappropriately given oxygen. Whilst we can only
speculate on unmeasured factors that could be driving
hospital attendance, it is of note that psychosocial issues
were not accounted for. Furthermore, in the longitudinal
analyses no evidence of a change in hospital admission
rates was seen when receiving oxygen, regardless of
whether this was appropriate. This suggests that prescrib-
ing oxygen as a bridge to LTOT assessment in borderline
patients on discharge is not likely to be of benefit, and
concurs with other studies of moderately hypoxaemic
COPD patients showing that receipt of oxygen does not
reduce hospitalisations [23].
We also chose to look at mortality in the patients
given oxygen, as it was apparent from the high Charlson
indices, poor lung function and ABG results that this
population was very unwell, and reducing mortality is a
key aim of LTOT use. We confirmed that respiratory
deaths were common, highly likely to occur within a few
years of starting oxygen, and more likely when oxygen is
indicated. It is important to note that we found no evi-
dence of harm resulting from oxygen prescription, par-
ticularly there were no admissions or deaths related to
oxygen use in patients given it against current guidance.
In our study LTOT was stopped in 40.3% of patients
after specialist review, a figure consistent with previous
work [24], suggesting our results are likely to be generalis-
able. It is possible that some of these patients may require
oxygen other than LTOT, and therefore assessment for
ambulatory oxygen alone – this was not a feature we
could examine in our data, although it has been sug-
gested that such assessments may be a drain on oxygen
assessment services [24]. There are significant numbers
of COPD patients who exhibit desaturation on exercise,
although they are normoxaemic at rest. This predicts
mortality [25] and subsequent need of LTOT [26]. Trials
of ambulatory oxygen have varied in their design and
outcome measures, such that a recent review concluded
further evidence was needed [5]. Cochrane continue to ad-
vocate individual assessment [27], rather than a guideline
based approach, for this reason. It remains unclear whether
home ambulatory oxygen use is beneficial; self-reported
improvements in activity levels and exercise tolerance didnot match well to objective measures of exercise capacity
in previous work [28]. Short burst oxygen therapy (SBOT)
has been the subject of a systematic review and meta-
analysis, and shown to provide no symptomatic benefits
[29]. Consequently use of home oxygen outside of the set-
ting of LTOT remains controversial [4]; when the Long
term Oxygen Treatment Trial (LOTT; http://clinicaltrials.
gov/show/NCT00692198) reports results, some of these
questions may be answered. Given this uncertainty, whilst
we acknowledge that lack of data on ambulatory oxygen
needs is a potential weakness we do not think it clinically
significant.
The further important limitations of our study are: (a)
due to the nature of the pre-2012 contracts with home
oxygen providers in England, we do not have concordance
data on actual oxygen use therefore the hospital admission
rates amongst COPD patients prescribed LTOT could not
be corrected to actual oxygen use; (b) No data was avail-
able for current smoking habits of LTOT users; (c).
Since there was no effect of oxygen (prescribed outside
evidence based LTOT guidelines) on emergency hospital
admission rates in our study, the economic benefits of
an oxygen assessment service broadly confirm the De-
partment of Health findings [7] that savings can be
made through multidisciplinary LTOT assessment ser-
vices. Locally our oxygen service does have any ring-
fenced budget for any extra secondary care staff, thus
we have not accounted for staff costs in our analyses,
although we recognize that these could reduce the im-
pact of the savings. Nevertheless our finding that oxy-
gen does not adversely impact admissions is of value,
and the potential for harm from inappropriate oxygen –
although not shown herein – should further strengthen
the support to introduce HOS-ARs across the UK. The
quality of assessment when seen by a specialist was higher,
as indicated by the fact that insufficient data to guide oxy-
gen prescription was available in patients given it by a
generalist, again concurring with guidance that experi-
enced practitioners should manage oxygen prescriptions.Conclusions
We conclude that robust oxygen assessment practices in
COPD patients are valuable to the health economy, by
direct savings, with no hidden costs or adverse events
related to admissions to hospital.Nomenclature
Secondary Uses Service (SUS), The Secondary Uses Service
(SUS) is primarily a data warehouse that provides access
to anonymous patient-based data for purposes other than
direct clinical care such as healthcare planning.
PCT, Primary Care Trusts were largely administrative
bodies, responsible for commissioning primary, community
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by clinical commissioning groups in the UK.
Healthcare Resource Group (HRG) code, The HRG sys-
tem is used by Payment by Results, an activity based pay-
ment system rolled out in the NHS in England since 2004,
the code comprising patient events that have been judged
to consume a similar level of resource.
Emergency spells/hospital spell, An emergency spell
relates to the whole hospital stay of a patient, from admis-
sion to discharge. For complex patients the Spell may con-
tain many episodes of care under different consultants.
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